JPRN-jRCTs031180027已完成未知
Clinical Research to Collect Safety Information Obtained Following Vaccination with Stamaril - STA00014
Ohmagari Norio0 个研究点目标入组 11,287 人开始时间: 2018年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 11,287
研究概览
简要总结
Adverse reaction rate was lower than previous studies/reports. AEs occurred to 696 cases (6.17%) including 671 (5.95%) with or suspected causal relationship. This rate is lower than those in Stamaril(R) SmPC. The lower rate could be a result of the study conducted approximate to the normal healthcare practices. AEs occurred out of study site were reported spontaneously and was not an all case follow-up. This could have led to a lower incidence rate.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 9month old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Person who may be exposed to the risk of yellow fever
- •2) Person aged 9 months or older on the day of vaccination with Stamaril
- •3) Person who gave written consent to get vaccinated with Stamaril which is unapproved in Japan, as an alternative to Yellow Fever Vaccine.
- •4) For persons aged 16 to less than 20 years, written consent from their legal representative is also needed in addition to written consent from the participant.
- •5) For persons aged less than 16 years, written consent from their legal representative is needed.
- •6) For persons aged 6 months to less than 9 months, persons who are or are possibly pregnant, persons aged 60 years or older, and persons infected with asymptomatic human immunodeficiency virus not associated with immune dysfunction, their doctor should judge that the expected benefits of vaccination outweigh the risks.
排除标准
- •1) Person with hypersensitivity to any of the additives contained in Stamaril, chicken eggs, or chicken meat proteins
- •2) Person with congenital or acquired immunodeficiency, such as those receiving immunosuppressive therapy with chemotherapy, systemic administration of corticosteroids, etc.
- •3) Person with a history of thymic dysfunction (including myasthenia gravis, thymoma, and thymectomy)
- •4) Person infected with symptomatic human immunodeficiency virus
- •5) Person infected with asymptomatic human immunodeficiency virus associated with immune dysfunction
- •6) Person with fever (more than 37.5 degrees)
- •7) Person who is judged by the doctor to have severe acute disease
- •8) Breastfeeding women who cannot suspend breastfeeding for at least 14 days after vaccination with Stamaril
- •9) Other persons who are judged by their doctor to be not appropriate for getting vaccinated prophylactically
研究者
相似试验
已完成
不适用
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
已完成
3 期
PD001JMedication-Refractory Tremor Dominant Idiopathic Parkinsons DiseaseJPRN-jRCTs032180081KAMEI TETSUMASA10
已完成
不适用
KADCYLA drug use surveillanceBreast cancerJPRN-UMIN000017702Chugai Pharmaceutical Co., Ltd.250
尚未招募
不适用
survey about adverse event after acupotomyKCT0004482Chung Yeon Korean Medicine Hospital100
已完成
不适用
Efectiveness of a Brief Protocol by a Low (6%) Concentration Gel Peroxide Hydrogen of Teeth BleachingTooth DiscolorationNCT02603354University of Chile31